CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,184,862)	$ (248,442)	$ (125,337)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	35,484	8,289	1,134
Share-based compensation	68,423	5,452	1,864
Deferred income taxes	(25,654)	0	0
Unrealized gain on equity securities	(80,231)	0	0
Other, net	20,254	2,667	(1,331)
Changes in assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	(32,941)	24,631	(201)
Other assets	(143,463)	(44,061)	(8,788)
Medical cost payable	475,461	78,591	21,826
Risk adjustment payable	742,075	100,974	70,137
Accounts payable and other liabilities	192,611	(3,962)	25,553
Unearned revenue	14,902	18,623	6,935
Net cash provided by (used in) operating activities	82,059	(57,238)	(8,208)
Cash flows from investing activities:
Purchases of investments	(1,017,588)	(916,823)	(300,325)
Proceeds from sales, paydown, and maturities of investments	926,901	463,887	238,330
Purchases of property and equipment	(30,414)	(6,474)	(793)
Business acquisitions, net of cash acquired	(431,791)	(230,332)	(31,855)
Net cash used in investing activities	(552,892)	(689,742)	(94,643)
Cash flows from financing activities:
Proceeds from issuance of preferred stock	0	711,200	423,800
Proceeds from issuance of common stock	11,390	1,241	260
Proceeds from short-term borrowings	355,000	0	0
Repayments of short-term borrowings	(200,000)	0	0
Payments for debt issuance costs	(3,391)	0	0
Proceeds from IPO	887,328	0	0
Payments for IPO offering costs	(6,686)	0	0
Net cash provided by financing activities	1,043,641	712,441	424,060
Net increase (decrease) in cash and cash equivalents	572,808	(34,539)	321,209
Cash and cash equivalents – beginning of year	488,371	522,910	201,701
Cash and cash equivalents – end of year	1,061,179	488,371	522,910
Supplemental disclosures of cash flow information:
Changes in unrealized (loss) gain on available-for-sale securities in OCI	(5,761)	1,444	1,173
Cash paid for interest	4,592	0	0
Supplemental schedule of non-cash activities:
Redeemable convertible preferred stock issued for acquisitions	134,944	97,825	3,500
Contingent consideration	(4,221)	0	5,716
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	$ 1,815,916	$ 0	$ 0